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A typical Indonesian kretek cigarette brand and an experimental kretek reference cigarette were com-
pared to the reference cigarette 2R4F in two 90-day inhalation studies. Male and female rats were
exposed nose-only to mainstream smoke for 6 hours daily, for 90 consecutive days. Biological endpoints
were assessed according to OECD guideline 413, with special emphasis on respiratory tract histopathol-
ogy and on lung inﬂammation (broncho-alveolar lavage ﬂuid levels of neutrophils, macrophages and
lymphocytes). Histopathological alterations included: in the nose, hyperplasia and squamous metaplasia
of the respiratory epithelium and squamous metaplasia and atrophy of the olfactory epithelium; in the
larynx, epithelial squamous metaplasia and hyperplasia; in the lungs, accumulation of macrophages in
alveoli and goblet cell hyperplasia in bronchial epithelium. The ﬁndings were qualitatively consistent
with observations from previous similar studies on conventional cigarettes. Compared to 2R4F cigarette,
however, kretek smoke exposure was associated with a pronounced attenuation of pulmonary inﬂamma-
tion and less severe histopathological changes in the respiratory tract. Neutrophilic inﬂammation was
also signiﬁcantly lower (>70%). These results are consistent with the observations made on smoke chem-
istry and in vitro toxicology. They do not support any increased toxicity of the smoke of kretek cigarettes
compared to conventional American-blended cigarettes.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
This publication is part of a series summarizing the in vitro and
in vivo toxicological assessment of kretek cigarettes. Smoke com-
position and biological activity of mainstream smoke (MS) from
marketed and experimental kretek cigarettes were evaluated on
a comparative basis in smoke chemistry analyses, and in vitro
and in vivo toxicity studies. The studies were designed to cover
three main topics: (1) characterization of kreteks and comparison
relative to American-blended cigarettes, (2) impact of blend type
and cloves, and (3) impact of ingredients used in kretek cigarettes.
Further in depth information of this assessment is described in the
lead publication (Roemer et al., 2014b).
In Part 2 of the current series of publications, both smoke
composition and biological activity ofMS from twomarketed kretek
cigarettes, including theGudangGaram International Filter (hereafterabbreviated as Garam), and a kretek reference (Kretek-R) cigarette
were evaluated relative to the reference cigarette 2R4F by smoke
chemistry analyses and in vitro toxicity studies (Piadé et al., 2014).
In this part the in vivo results of two independent 90-day inhalation
studies, inwhichGaram and Kretek-R cigaretteswere benchmarked
against the reference cigarette 2R4F, are presented.2. Materials and methods
2.1. General
Garam and Kretek-R cigarettes were evaluated against the
American-blended reference cigarette 2R4F in two separate 90-
day inhalation studies (Study A and B, respectively) conducted in
compliance with the Organization for Economic Co-operation and
Development (OECD) Principles on Good Laboratory Practice
(GLP) (as revised in 1997) and according to the OECD guideline
413 (OECD, 1981).
The inhalation studies were conducted in an AAALAC (Associa-
tion for Assessment and Accreditation of Laboratory Animal Care
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gium (Philip Morris Research Laboratories) where the care and
use of rats was conformed to the American Association for Labora-
tory Animal Science Policy on the Humane Care and Use of Labora-
tory Animals (www.aalas.org). The studies were approved by the
local Institutional Animal Care and Use Committee according to
Belgian legislation.
Detailed descriptions regarding the chemical analyses, toxico-
logical assays and statistical procedures can be found in the ﬁrst
of this series of publications (Roemer et al., 2014b). The smoke gen-
eration, the analytical characterization of the test atmosphere, the
selection and care of animals and the selection of exposure param-
eters were performed as previously detailed (Vanscheeuwijck et al.,
2002). They can be summarized as follows:
2.2. Cigarettes
The cigarettes tested were a commercial Indonesian kretek cig-
arette, the Gudang Garam International Filter (abbreviated Garam)
and an experimental kretek reference cigarette (Kretek-R)
designed to be representative of an average kretek cigarette. A
detailed description of the design and performance of both ciga-
rettes can be found in Part 2 of this publications series (Piadé
et al., 2014).
2.3. Smoke generation
A rotary smoking machine, operated according to International
Organization for Standardization (ISO) 3308 conditions (ISO-3308,
2000) was used to continuously generate MS following ISO 4387
standard requirements (ISO-4387-4, 2000). Smoke was diluted at
machine exit with ﬁltered and conditioned air to match the target
concentration of total particulate matter (TPM) and fed to the
exposure chambers.
2.4. Exposure
Both inhalation studies were performed using TPM target con-
centrations of 100 lg/l (Low), 150 lg/l (Medium) and 200 lg/l
(High) for both kretek cigarettes as well as for the reference ciga-
rette 2R4F. Outbred male and female Sprague–Dawley rats were
exposed nose-only for 6 hours daily, for 90 consecutive days. A
control group of animals was exposed to ﬁltered, conditioned airTable 1
Test atmosphere in exposure chambers for the two separate 90-day inhalation studies (St
Group TPM (lg/l) Particle size Nicotine (lg/l) Carbon m
MMAD (lm) GSD
Study A
Sham <0.9 – – <0.03 <1.5
2R4F Low 99.9 ± 4.9 0.52 1.67 5.43 ± 0.32 114.3 ± 5
2R4F Medium 149.8 ± 7.2 0.52 1.66 8.14 ± 0.91 165.9 ± 8
2R4F High 204.6 ± 9.0 0.53 1.69 12.03 ± 1.10 227.5 ± 9
Garam Low 99.6 ± 7.7 0.56 1.70 5.30 ± 0.68 48.6 ± 3
Garam Medium 145.5 ± 10.5 0.58 1.70 7.20 ± 0.82 68.4 ± 3
Garam High 200.7 ± 12.6 0.58 1.72 8.89 ± 1.27 88.3 ± 5
Study B
Sham <1.6 – – <0.03 <4.5
2R4F Low 98.0 ± 3.9 0.69 1.72 7.65 ± 1.02 112.0 ± 5
2R4F Medium 149.3 ± 6.1 0.60 1.67 11.53 ± 1.00 168.5 ± 9
2R4F High 197.6 ± 10.0 0.60 1.70 15.24 ± 0.62 208.4 ± 1
Kretek-R Low 98.1 ± 5.9 0.65 1.80 6.84 ± 0.72 62.7 ± 3
Kretek-R Medium 147.8 ± 6.0 0.68 1.69 9.58 ± 0.82 90.3 ± 3
Kretek-R High 198.6 ± 9.1 0.68 1.73 12.01 ± 1.07 117.1 ± 5
Results represent medians or means ± standard deviation.
Abbreviations: MMAD, mass median aerodynamic diameter; GSD, geometric standard dev
TPM, total particulate matter.(Sham). The study was performed with 10 rats per group, per sex
and per necropsy time point. The mean temperature of the test
atmosphere was 21.6 C and relative humidity 54%. The inhalation
period began with a dose adaptation period (i.e., 1=4, ½, and 3=4 of the
ﬁnal daily exposure duration on days 1, 2, and 3, respectively). An
interim assessment was conducted for all end points after 35 days
of exposure, and post-inhalation animals were allowed a 42-day
recovery before sacriﬁce to investigate reversibility, persistence,
and delayed occurrence of smoke-related effects.
To characterize the test atmosphere and check the reproducibil-
ity of MS generation and dilution, the concentration of TPM and
carbon monoxide (CO) was determined daily. In addition the air-
borne concentrations of acetaldehyde, acrolein, formaldehyde
and nicotine were determined weekly, and the particle size distri-
bution was assessed on two different occasions.
2.5. Endpoints
General health of animals was monitored by body weight and
food consumption. The endpoints analyzed included all parameters
speciﬁed in the OECD guideline 413 (OECD, 1981), and were deter-
mined at the interim sacriﬁce (after 35 days) and at the end of the
inhalation period.
Weight was determined for major organs. Lung inﬂammatory
response was assessed by quantiﬁcation of neutrophils, lympho-
cytes, and alveolar macrophages in broncho-alveolar lavage ﬂuid
(BALF) (Friedrichs et al., 2006). Histopathological examination
was performed with an extended assessment of larynx, tracheal
bifurcation, and lung.3. Results
The observations made after the 35-day interim period were in
line with those made at the end of the 90-day exposure period, and
the following discussion is thus based on the latter. Data are how-
ever included in the atmosphere characterization or the animals
body weight development.
3.1. Test atmospheres characterization
The concentrations of both TPM and the monitored smoke con-
stituents were found to be stable throughout the 90-day exposure
period, and target TPM concentrations were achieved (Table 1).udy A and B).
onoxide (ppm) Acetaldehyde (lg/l) Acrolein (lg/l) Formaldehyde (lg/l)
– – –
.6 4.61 ± 0.38 0.35 ± 0.03 0.13 ± 0.01
.1 6.61 ± 0.51 0.52 ± 0.04 0.19 ± 0.03
.2 8.57 ± 1.46 0.65 ± 0.11 0.23 ± 0.04
.7 1.62 ± 0.13 0.16 ± 0.02 0.21 ± 0.02
.8 2.25 ± 0.34 0.22 ± 0.03 0.29 ± 0.04
.6 2.89 ± 0.28 0.30 ± 0.03 0.35 ± 0.04
– – –
.8 6.69 ± 0.32 0.72 ± 0.04 0.13 ± 0.01
.3 9.90 ± 0.48 1.10 ± 0.10 0.19 ± 0.02
3.3 12.90 ± 0.68 1.40 ± 0.08 0.24 ± 0.02
.9 3.27 ± 0.16 0.46 ± 0.02 0.23 ± 0.02
.4 4.69 ± 0.10 0.66 ± 0.02 0.33 ± 0.02
.0 5.73 ± 0.62 0.80 ± 0.09 0.42 ± 0.03
iation; Garam, Gudang Garam International Filter; Kretek-R, kretek reference cigarette;
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namic diameter (MMAD) and its geometric standard deviation
(GSD), indicated that particles were equally respirable in all
smoke-exposed groups.
At the lowest target concentration of TPM (100 lg/l) the nico-
tine concentrations in the test atmospheres were similar for Garam
and the reference cigarette 2R4F, but 10% lower for Kretek-R ciga-
rette. Compared to the medium and high TPM target concentra-
tions for the reference cigarette 2R4F, nicotine concentrations in
the exposure atmospheres were approximately 10% and 25% lower
for the Garam and Kretek-R cigarettes, respectively. With regards
to the other smoke constituents monitored in the exposure cham-
bers, concentrations of CO, acrolein and acetaldehyde were in all
cases substantially lower in the test atmospheres generated from
kretek cigarettes than in those generated from the reference ciga-
rette 2R4F at similar target concentration TPM levels. In contrast,
the concentration of formaldehyde was higher, which is in lineFig. 1. Mean body weights of male (A) and female (B) rats exposed to fresh air (sham) and
study (Study A).with the cigarette smoke chemical composition data (Piadé et al.,
2014).
3.2. Clinical observations
After daily exposure, Harderian gland secretion and wet fur
were observed in sham- and smoke-exposed groups; incidences
in the smoke-exposed groups were higher than in the sham group.
In some cases, increased reaction to sound and touch, decreased
turning reﬂex, and decreased gripping ability were observed. Such
observations have also been made in previous cigarette smoke
inhalation studies (Vanscheeuwijck et al., 2002) and are considered
to be related to tube restraint and/or smoke exposure. There were
no numerical differences in clinical observations or mortality
between the Garam or Kretek-R and the reference cigarette 2R4F
groups that could be considered to indicate an inﬂuence of the cig-
arette type.smoke of the Garam and the reference 2R4F cigarettes during the 90-day inhalation
Fig. 2. Total nicotine metabolites and 3-hydroxypropylmercapturic acid (HPMA) levels in 24-h urine samples from male (A) and female (B) rats as a function of exposure
chamber precursor concentration (Study A) Note: no regression line is given in the HPMA vs. acrolein plot because the relationship of the urinary biomarker level to acrolein
exposure may not be linear (Zheng et al., 2013), and because other sources coexist for HPMA, as demonstrated by the non-zero sham level.
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Rats gained weight throughout the studies in all groups,
although animals exposed to smoke had reduced body weight rel-
ative to sham-treated animals. After the 90-day exposure to ciga-
rette smoke, body weight was about 10–15% lower than sham for
male animals and approximately 8–13% lower than sham for
female animals. As shown in Fig. 1, no signiﬁcant difference in ani-
mals body weight was observed throughout the 90-day inhalation
period whether animals were exposed to smoke from the reference
cigarette 2R4F or the Garam cigarette (Study A). The same was
observed in Study B with the Kretek-R (data not shown). After
the post-inhalation period, however, animals that had been
exposed to smoke from Garam cigarettes generally had slightly
higher body weights than animals exposed to the smoke of the ref-
erence cigarette 2R4F. This trend was more important in the case of
female animals and was observed in both studies A and B.3.4. Respiratory physiology
In general, respiratory frequency, tidal volume, and respiratory
minute volume were lower in smoke-exposed groups than in the
sham group. There were sporadic statistically signiﬁcant differ-
ences between the various groups, but no overall trends were
noted (data not shown).
3.5. Urinary nicotine metabolites
Urinary nicotine metabolites were determined according to
Rustemeier et al. (1993). The relative abundances of the measured
urinary nicotine metabolites (nicotine-N0-oxide, nornicotine,
cotinine, 30-hydroxycotinine, 50-hydroxycotinine, norcotinine,
4-(3-pyridyl)-4-oxobutyric acid, 4-(3-pyridyl)-4-hydroxybutyric
acid, and 3-pyridylacetic acid) in 24-hour samples were similar
in all smoke-exposed groups within each gender. The total amount
Table 2
Blood neutrophil counts after 90-day inhalation exposure.
Group Neutrophils (109/l)
Male Female
Study A
Sham 0.98 ± 0.14 0.71 ± 0.06
2R4F low 1.21 ± 0.21 0.74 ± 0.10
2R4F Medium 1.35 ± 0.21 1.12 ± 0.16
2R4F high 1.69 ± 0.28 1.45 ± 0.18⁄⁄
Garam low 1.03 ± 0.11 0.55 ± 0.09
Garam medium 0.86 ± 0.13 0.82 ± 0.12
Garam high 1.32 ± 0.18 1.14 ± 0.23
Study B
Sham 0.66 ± 0.14 0.59 ± 0.07
2R4F low 1.33 ± 0.12⁄ 0.95 ± 0.13
2R4F medium 1.47 ± 0.20⁄⁄ 1.25 ± 0.16⁄
2R4F high 1.63 ± 0.14⁄⁄⁄ 1.75 ± 0.42⁄⁄
Kretek-R low 1.00 ± 0.13 0.71 ± 0.13
Kretek-R medium 0.88 ± 0.13 1.19 ± 0.17
Kretek-R high 1.32±0.18⁄ 1.01 ± 0.14
Results are presented as mean ± standard error.
Difference from sham; Signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001.
(p-Value from 2-way ANOVA followed by Dunnett posthoc test).
Abbreviations: Garam, Gudang Garam International Filter; Kretek-R, kretek reference
cigarette.
Fig. 3. Neutrophil counts in the BALF frommale (A) and female (B) animals exposed
to smoke from 2R4F and Garam cigarettes (Study A).
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animals correlated linearly with the nicotine concentration in the
test atmosphere, as demonstrated in the case of Garam and thereference cigarette 2R4F in Fig. 2. A similar correlation was also
observed between 3-hydroxypropylmercapturic acid (HPMA), bio-
marker of exposure to acrolein (Carmella et al., 2007), and the
acrolein concentration in the test atmosphere (Fig. 2). Similar
results were obtained in the case of the Kretek-R cigarette (data
not shown).
3.6. Carboxyhemoglobin and other gas phase biomarkers
The steady-state concentrations of carboxyhemoglobin in blood
ranged between 12% and 25% in the low and high reference ciga-
rette 2R4F groups, respectively, and between 6% and 13% in the
low and high kretek cigarette groups, respectively. These values
are consistent with CO concentrations measured in the test atmo-
sphere of the different cigarettes tested. The concentration of 1,3-
butadiene was not measured in the test atmosphere, but recovered
amounts in 24-hour urine of 3-monohydroxybutylmercapturic
acid (MHBMA), a biomarker of exposure to 1,3-butadiene, corre-
lated linearly with test atmosphere concentrations of CO, a good
proxy for gases that do not exhibit adsorption to surfaces (data
not shown).
3.7. Hematology
At the end of the 90-day exposure period, a statistically signif-
icant increase in erythrocyte count, hematocrit, and hemoglobin
was observed in the animals of both the reference cigarette 2R4F
High and Kretek-R High groups relative to the animals of the
sham-exposed group (data not shown). A similar increase was
not observed in the animals of the Garam groups and there was
no difference between smoke-exposed groups. Compared to sham,
the neutrophil count was statistically signiﬁcantly increased in a
dose-dependent manner in animals exposed to MS from the refer-
ence cigarette 2R4F, but reached statistical signiﬁcance only in the
Kretek-R High group. The neutrophil count was generally lower in
animals exposed to smoke from kretek cigarettes than in those
exposed to similar concentrations of TPM from the reference ciga-
rette 2R4F, and the difference reached statistical signiﬁcance. Data
are given in Table 2.
3.8. Clinical chemistry
The observed changes in clinical chemistry parameters are con-
sistent with the observations from previous cigarette smoke inha-
lation studies (Vanscheeuwijck et al., 2002). These included an
increase in the activity of alanine aminotransferase, aspartate ami-
notransferase, and alkaline phosphatase (data not shown). The
concentrations of total cholesterol, triglyceride, and total protein
were decreased compared to sham, but there were no differences
among the smoke-exposed groups.
3.9. Differential cell count in BALF
All smoke-exposed groups had a statistically signiﬁcant
increase in the number of neutrophils in the BALF, compared to
sham. This increase was TPM concentration-dependent. The neu-
trophil counts were statistically signiﬁcantly lower in the BALF
from animals exposed to smoke from Garam and Kretek-R ciga-
rettes than in those exposed to similar TPM levels of smoke from
the reference cigarette 2R4F (Fig. 3, Tables 3 and 4). The number
of lymphocytes and total amount of cells recovered from BALF
were higher in reference cigarette 2R4F-exposed rats than in
sham-exposed rats, but this was not the case for kretek cigarette-
exposed rats. Relevant BALF cell differential results are summa-
rized in Tables 3 and 4. Table 5 further summarizes all observations
for which data were signiﬁcantly different when groups exposed to
Table 3
Differential cell count in BALF after 90-day inhalation exposure; Garam and reference cigarette 2R4F (Study A).
Cell type Gender Sham 2R4F low 2R4F medium 2R4F high Garam low Garam medium Garam high
All cell types M 7.4 ± 0.6 10.5 ± 0.8⁄ 11.2 ± 0.8⁄⁄ 12.2 ± 1.0⁄⁄⁄ 7.4 ± 0.6 7.4 ± 0.6 7.3 ± 0.8
F 5.6 ± 0.6 6.1 ± 0.4 8.5 ± 0.7⁄⁄⁄ 7.7 ± 0.6⁄ 4.8 ± 0.3 6.0 ± 0.5 5.6 ± 0.4
Neutrophils M 0.027 ± 0.007 0.65 ± 0.11⁄⁄⁄ 1.50 ± 0.21 ⁄⁄⁄ 2.13 ± 0.22⁄⁄⁄ 0.062 ± 0.008⁄ 0.14 ± 0.03⁄⁄⁄ 0.43 ± 0.13⁄⁄⁄
F 0.011 ± 0.003 1.01 ± 0.09⁄⁄⁄ 2.07 ± 0.32⁄⁄⁄ 2.13 ± 0.28⁄⁄⁄ 0.139 ± 0.033⁄⁄ 0.257 ± 0.038⁄⁄⁄ 0.56 ± 0.19⁄⁄⁄
Alveolar macrophages M 7.2 ± 0.6 9.7 ± 0.7 9.6 ± 0.8 9.9 ± 1.1 7.2 ± 0.6 7.2 ± 0.6 6.8 ± 0.8
F 5.5 ± 0.6 5.0 ± 0.4 6.4 ± 0.6 5.4 ± 0.5 4.6 ± 0.3 5.7 ± 0.5 5.0 ± 0.4
Lymphocytes M 0.120 ± 0.018 0.157 ± 0.034 0.144 ± 0.014 0.221 ± 0.025⁄⁄ 0.060 ± 0.010 0.054 ± 0.008 0.067 ± 0.011
F 0.096 ± 0.038 0.103 ± 0.015 0.121 ± 0.018 0.134 ± 0.019 0.066 ± 0.014 0.044 ± 0.007 0.053 ± 0.006
Cell numbers reported as 106 cells/right lung. Results are presented as mean ± standard error.
Difference from sham; Signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Abbreviations: Garam, Gudang Garam International Filter; Kretek-R, kretek reference cigarette; BALF, broncho-alveolar lavage ﬂuid; M, male; F, female.
Table 4
Differential cell count in BALF after 90-day inhalation exposure; Kretek-R and reference cigarette 2R4F (Study B).
Cell type Gender Sham 2R4F low 2R4F medium 2R4F high Kretek-R low Kretek-R medium Kretek-R high
All cell types M 65.0 ± 5.7 97.0 ± 6.2⁄⁄ 103.8 ± 11.9⁄⁄ 116.5 ± 7.8⁄⁄⁄ 67.3 ± 3.8 80.8 ± 7.1 91.9 ± 6.1⁄
F 44.6 ± 4.8 67.1 ± 5.1 107.0 ± 11.4⁄⁄⁄ 116.8 ± 19.5⁄⁄⁄ 66.9 ± 8.9 69.0 ± 8.1 78.4 ± 7.6⁄⁄
Neutrophils M 0.70 ± 0.43 8.62 ± 1.70⁄⁄⁄ 16.58 ± 2.59⁄⁄⁄ 27.50 ± 2.80⁄⁄⁄ 1.48 ± 0.30⁄⁄⁄ 2.94 ± 0.38⁄⁄⁄ 3.92 ± 0.50⁄⁄⁄
F 0.68 ± 0.56 6.68 ± 0.77⁄⁄⁄ 19.38 ± 3.13⁄⁄⁄ 31.67 ± 3.76⁄⁄⁄ 1.15 ± 0.29⁄⁄⁄ 6.10 ± 1.42⁄⁄⁄ 10.20 ± 1.94⁄⁄⁄
Alveolar macrophages M 63.7 ± 5.6 87.1 ± 5.2⁄ 85.8 ± 11.0 87.2 ± 6.9⁄ 65.2 ± 3.5 77.1 ± 6.9 87.1 ± 6.3⁄
F 43.5 ± 4.5 59.7 ± 5.3 85.8 ± 10.4⁄ 83.4 ± 16.0⁄ 65.3 ± 8.7 62.3 ± 7.6 67.5 ± 6.9
Lymphocytes M 0.65 ± 0.16 1.23 ± 0.13⁄⁄ 1.40 ± 0.25⁄⁄⁄ 1.76 ± 0.21⁄⁄⁄ 0.58 ± 0.11 0.71 ± 0.08 0.85 ± 0.17
F 0.38 ± 0.09 0.71 ± 0.06⁄⁄ 1.72 ± 0.35⁄⁄⁄ 1.76 ± 0.36⁄⁄⁄ 0.46 ± 0.08 0.61 ± 0.08⁄ 0.63 ± 0.06⁄
Cell numbers reported as 106 cells/right lung. Results are presented as mean ± standard error.
Difference from sham; Signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Abbreviations: Garam, Gudang Garam International Filter, Kretek-R, kretek reference cigarette; BALF, broncho-alveolar lavage ﬂuid; M, male; F, female.
Table 5
Signiﬁcance of differences in BALF cell count after the 90-day inhalation study between animals exposed to MS from reference cigarette 2R4F and those exposed to MS from each
of the kretek cigarettes.
Measured parameter Study A: Garam vs. 2R4F Study B: Kretek-R vs. 2R4F
Male rats Female rats Male rats Female rats
All cell types ⁄⁄⁄; ⁄⁄; ⁄⁄⁄; ⁄⁄;
Neutrophils ⁄⁄⁄; ⁄⁄⁄; ⁄⁄⁄; ⁄⁄⁄;
Alveolar macrophages ⁄⁄⁄; = = =
Lymphocytes ⁄⁄⁄; ⁄⁄⁄; ⁄⁄⁄; ⁄⁄⁄;
Difference among cigarettes; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Symbols, ; indicates response lower in kretek cigarette relative to 2R4F; =indicates no trend.
Abbreviations: Garam, Gudang Garam International Filter; Kretek-R, kretek reference cigarette.
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exposed to equivalent TPM levels of smoke from the reference cig-
arette 2R4F.
3.10. Non-respiratory tract organs
Minimal to mild thymus atrophy was observed in male and
female rats of all smoke-exposed groups. This ﬁnding is considered
to be caused by general stress associated with exposure treatment
and smoke irritation (Gruver and Sempowski, 2008) and was also
reﬂected in a decrease of the weight of the thymus relative to
the body weight (Table 6). In general, the magnitude of the effect
was more pronounced in the reference cigarette 2R4F smoke-
exposed rats than in Kretek-R or Garam cigarette smoke-exposed
rats. However, relative to sham, adrenal absolute weights were
increased in a TPM-concentration-dependent way, but the changes
were similar upon exposure to the smoke from the different ciga-
rettes. Other ﬁndings occasionally reached statistical signiﬁcance
but did not follow a dose response and have not been consistentlyobserved in other inhalation studies. They are therefore considered
incidental.
3.11. Histopathology of the respiratory tract
Histopathological ﬁndings consistent with previous inhalation
studies of cigarette smoke were observed in the smoke-exposed
groups. These include histopathological changes in the nose
(hyperplasia and squamous metaplasia of the respiratory epithe-
lium, squamous metaplasia and atrophy of the olfactory epithe-
lium), larynx (hyperplasia of the squamous epithelium and
squamous metaplasia of the pseudostratiﬁed epithelium), and
lungs (accumulation of macrophages and goblet cell hyperplasia)
as detailed in Tables A–D in the Appendix. The histological changes
observed in the larynx, lungs and trachea are also reﬂected in the
changes of the weights (relative to body weight) of these organs
(Table 6).
Signiﬁcant differences in histopathological ﬁndings were
observed between animals exposed to smoke from Garam or
Table 6
Organ weights, relative to body weight, after 90-day inhalation exposure to the MS of reference cigarette 2R4F, Garam and Kretek-R cigarettes.
Group Lungs with Trachea and Larynx (104) Thymus (104)
Male Female Male Female
Study A
Sham 35.09 ± 0.53 46.71 ± 1.02 5.76 ± 0.49 10.39 ± 1.02
2R4F Low 40.49 ± 1.19⁄⁄⁄ 55.20 ± 0.80⁄⁄⁄ 5.22 ± 54 8.63 ± 0.96
2R4F Medium 43.07 ± 0.67⁄⁄⁄ 60.85 ± 0.97⁄⁄⁄ 5.03 ± 0.39 6.51 ± 0.49
2R4F High 46.05 ± 1.27⁄⁄⁄ 59.35 ± 1.21⁄⁄⁄ 4.93 ± 0.50 6.61 ± 0.64
Garam Low 39.64 ± 0.93⁄⁄ 50.88 ± 1.06⁄ 5.27 ± 0.38 8.52 ± 0.44
Garam Medium 40.65 ± 0.84⁄⁄⁄ 55.43 ± 0.93⁄⁄⁄ 5.07 ± 0.39 7.94 ± 0.54
Garam High 42.65 ± 0.84⁄⁄⁄ 54.73 ± 0.85⁄⁄⁄ 4.54 ± 0.46 10.24 ± 2.98
Study B
Sham 36.25 ± 0.74 48.27 ± 0.63 4.65 ± 0.44 7.24 ± 0.50
2R4F Low 44.23 ± 0.95⁄⁄⁄ 55.96 ± 1.40⁄⁄⁄ 4.53 ± 0.41 5.20 ± 0.32⁄
2R4F Medium 47.36 ± 2.43⁄⁄⁄ 60.46 ± 2.11⁄⁄⁄ 3.22 ± 0.28 4.47 ± 0.50⁄⁄⁄
2R4F High 51.77 ± 0.73⁄⁄⁄ 64.90 ± 1.41⁄⁄⁄ 2.83 ± 0.33⁄⁄ 3.77 ± 0.32⁄⁄⁄
Kretek-R Low 40.81 ± 0.92 52.20 ± 1.45 4.41 ± 0.39 6.30 ± 0.61
Kretek-R Medium 43.43 ± 1.01⁄⁄ 55.53 ± 1.34⁄⁄ 3.91 ± 0.42 5.22 ± 0.47⁄
Kretek-R High 45.77 ± 1.06⁄⁄⁄ 57.86 ± 1.39⁄⁄⁄ 3.47 ± 0.20 4.42 ± 0.40⁄⁄⁄
Results are presented as mean ± standard error.
Difference from sham; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Abbreviations: Garam, Gudang Garam International Filter; Kretek-R, kretek reference cigarette.
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TPM from the reference cigarette 2R4F. The histopathological
results were qualitatively similar but were generally less severe
in animals exposed to smoke from Garam and Kretek-R cigarettes
than in those exposed to smoke from the reference cigarette 2R4F.
While differences between the reference cigarette 2R4F and
Kretek-R cigarette smoke-exposed groups reached statistical sig-
niﬁcance in both male and female rats, the difference between
Garam cigarette and the reference cigarette 2R4F smoke-exposed
groups was only signiﬁcant in female animals. No difference was
observed on the effects on the epithelia of the male rats when com-
paring the reference cigarette 2R4F and the Garam cigarette
smoke-exposed groups. This is probably due to the fact that, in
general, all effects observed in the epithelia of the reference
cigarette 2R4F-exposed male rats during the study of the Kretek-R
cigarette were unexpectedly low (in some cases absent). Tables 7
and 8 list the observations which were signiﬁcantly different
between animals of either gender exposed to Garam or Kretek-R
cigarette smoke and the corresponding reference cigarette 2R4F
groups. Most histopathological ﬁndings had reversed (completely
or partially) at the end of the 42-day recovery period.
4. Discussion
The marketed kretek cigarette with the highest TPM delivery
(Garam) and an experimental kretek reference cigarette (Kretek-
R) were tested in parallel with the American-blended reference
cigarette 2R4F in two separate 90-day inhalation studies on rats.
The exposure was assessed by monitoring the levels of different
smoke constituents in the exposure chamber and the levels of
some of their respective urinary biomarkers. Similar urinary levels
of nicotine metabolites were observed in kretek- and the reference
cigarette 2R4F-exposed animals when adjusted for the test atmo-
sphere nicotine concentration. These results suggests similar
smoke uptake by the animals occurred for both cigarette types,
and this was further corroborated by similarity in the respiratory
function parameters across all smoke-exposed groups. Further-
more, the measurements of metabolites of gas phase smoke con-
stituents (CO, acrolein and 1,3-butadiene) were consistent with
increased TPM exposure.
Inhalation studies have been performed with various animal
species to assess cigarette smoke toxicity, as detailed in a review
(Coggins, 2010). Many of the ‘smoke-related’ observations madefrom assaying both the kretek cigarettes and the American-
blended reference cigarette 2R4F in the present study were similar
to those reported from several MS inhalation studies in rats (Baker
et al., 2004; Coggins et al., 2011; Roemer et al., 2012; Terpstra et al.,
2003; Vanscheeuwijck et al., 2002). However, there are notable dif-
ferences between kretek cigarette smoke-exposed groups and the
groups exposed to smoke from the reference cigarette 2R4F. At
equivalent TPM concentrations in the test atmosphere, the severity
of almost all observed adverse effects was lower in groups exposed
to smoke from both Garam and Kretek-R cigarettes than in those
exposed to the reference cigarette 2R4F. In particular, both kretek
cigarettes demonstrated less severity of most histopathological
endpoints in the respiratory tract and a pronounced attenuation
in pulmonary inﬂammation when compared to the reference ciga-
rette 2R4F.
One exception to this general pattern of histopathological ﬁnd-
ings was observed in the context of Study B (Kretek-R cigarettes). It
comes as a consequence of the unexpected low response to the
smoke from the reference cigarette 2R4F observed on the respira-
tory tract organs in the male rats (and not the female animals). The
2R4F cigarette was used as a reference in many different inhalation
studies, and no such effect was ever observed in these other stud-
ies; notably no such effect was observed when testing the refer-
ence cigarette 2R4F in Study A. Therefore, this observation
cannot be considered reliable, whilst no obvious cause for this
effect could be identiﬁed.
Lung inﬂammation was lower in kretek cigarette smoke-
exposed than in the reference cigarette 2R4F-exposed rats, as evi-
denced by the lower number of neutrophils recovered from BALF
(absolute numbers and% of total free lung cells) as well as the
lower histopathological scores on the presence of alveolar macro-
phages. This is corroborated by the neutrophil counts in the blood.
These effects were similar to those reported for an Electrically
Heated Cigarette Smoking System (EHCSS) by Werley and his team
at the same range of TPM exposures (100, 150 and 200 lg/l)
(Werley et al., 2008).
Previous MS inhalation studies have demonstrated that expo-
sure to the isolated gas/vapor phase (GVP) ismainly associatedwith
histopathological changes in the nose of rats (Friedrichs et al.,
2006), which likely reﬂects the presence of known irritants in the
GVP (van der Toorn et al., 2013). The signiﬁcant reduction in the
majority of analyzed GVP constituents in kretek cigarettes relative
to 2R4F cigarettes (Piadé et al., 2014) is therefore likely to explain at
Table 7
Histopathological endpoints statistically signiﬁcantly different between reference cigarette 2R4F- and Garam cigarette smoke-exposed rats (Study A).
Localization Tissue type Observation Garam vs. 2R4F
Male Female
Nose level 1 Respiratory epithelium Goblet cell hyperplasia = ⁄"
Lumen Exudate ⁄" =
Nose level 2 Respiratory epithelium Reserve cell hyperplasia = ⁄⁄⁄;
Squamous metaplasia without corniﬁcation = ⁄⁄⁄;
Olfactory epithelium Atrophy = ⁄⁄⁄;
Squamous metaplasia without corniﬁcation = ⁄⁄⁄;
Olfactory region Loss of nerve bundles = ⁄⁄⁄;
Nose level 3 Olfactory epithelium Atrophy = ⁄⁄;
Squamous metaplasia without corniﬁcation = ⁄⁄;
Olfactory region Loss of nerve bundles = ⁄⁄;
Nose level 4 Olfactory epithelium Atrophy = ⁄⁄;
Squamous metaplasia without corniﬁcation = ⁄;
Larynx Ventral depression Squamous metaplasia without corniﬁcation = ⁄;
Vocal cords, Upper medial region Squamous metaplasia without corniﬁcation ⁄⁄⁄; =
Pseudostratiﬁed epithelium Squamous metaplasia without corniﬁcation = ⁄;
Tracheal bifurcation Respiratory epithelium Goblet cell hyperplasia = ⁄;
Left lung Respiratory epithelium Goblet cell hyperplasia = ⁄;
Alveoli Alveolar macrophages without pigmentation = ⁄⁄;
Alveolar macrophages with pigmentation ⁄⁄⁄; ⁄⁄⁄;
Difference among cigarettes; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
" indicates response higher in Garam relative to the reference cigarette 2R4F.
; indicates response lower in Garam relative to the reference cigarette 2R4F.
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ings in rats exposed to the kretek cigarette smoke. Conversely, it
was also reported (Friedrichs et al., 2006) that the particulate phase
of smoke is mostly responsible for the inﬂammation of the lung and
the hyperplastic andmetaplastic epithelial changes in the larynx. In
addition to the effects caused by the different particulate phase
composition of the smoke from kretek and 2R4F cigarettes (Piadé
et al., 2014), the speciﬁc chemical and pharmacological effects of
eugenol could also contribute to the lower severity of end points
in the larynx and the lungs of kretek cigarette smoke-exposed rats.
A separate set of studies (Parts 4 and 5 in the current publication
series) was therefore performed to discern the contributions fromTable 8
Histopathological endpoints statistically signiﬁcantly different between reference cigarett
Localization Tissue type Observati
Nose level 1 Respiratory epithelium Reserve c
Squamou
Squamou
Loss of go
Nose level 2 Respiratory epithelium Reserve c
Squamou
Olfactory epithelium Atrophy
Squamou
Olfactory region Loss of ne
Nose level 3 Olfactory epithelium Atrophy
Squamou
Olfactory region Loss of ne
Nose level 4 Olfactory epithelium Atrophy
Squamou
Olfactory region Loss of ne
Larynx Vocal cords, Lower medial region Squamou
Left lung Respiratory epithelium Goblet ce
Alveoli Alveolar m
Alveolar m
Difference among cigarettes; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value
" indicates response higher in Kretek-R relative to the reference cigarette 2R4F.
; indicates response lower in Kretek-R relative to the reference cigarette 2R4F.clove, clove components and tobacco type to biological activity
in vitro and in vivo (Roemer et al., 2014a, c).
As detailed in the lead publication (Roemer et al., 2014b), one
acute and two sub-acute animal inhalation studies performed in
the 80ies yielded differing results regarding the in vivo toxicity of
kretek cigarettes smoke (Clark, 1989, 1990; Lavoie et al., 1986).
The present studies, together with the other 90-day inhalation
studies performed according to the OECD guideline 413 (OECD,
1981) reported in this special supplement, may be used as
scientiﬁc evidence to characterize the hazard potential of kretek
cigarettes. Overall, the observations from the inhalation studies
are consistent with the observations made on smoke chemistrye 2R4F- and Kretek-R-cigarette smoke exposed rats (Study B).
on Kretek-R vs. 2R4F
Male Female
ell hyperplasia ⁄; =
s metaplasia with corniﬁcation ⁄⁄; ⁄;
s metaplasia without corniﬁcation ⁄⁄; =
blet cells ⁄; ⁄⁄;
ell hyperplasia ⁄⁄⁄; ⁄⁄⁄;
s metaplasia without corniﬁcation ⁄; ⁄;
⁄⁄⁄; ⁄⁄⁄;
s metaplasia without corniﬁcation ⁄⁄⁄; ⁄⁄⁄;
rve bundles ⁄⁄⁄; ⁄⁄⁄;
⁄⁄; ⁄⁄⁄;
s metaplasia without corniﬁcation ⁄⁄; ⁄⁄⁄;
rve bundles ⁄⁄; ⁄⁄⁄;
⁄⁄; ⁄⁄⁄;
s metaplasia without corniﬁcation ⁄⁄; ⁄⁄;
rve bundles ⁄⁄; ⁄⁄⁄;
s hyperplasia without corniﬁcation = ⁄"
ll hyperplasia = ⁄;
acrophages without pigmentation ⁄⁄⁄; ⁄⁄⁄;
acrophages with pigmentation ⁄⁄⁄; ⁄⁄⁄;
from 2-way ANOVA followed by Dunnett posthoc test).
Table A
Histopathological ﬁndings in the respiratory tract of male rats after the 90-day inhalation period to MS of the reference cigarette 2R4F, Garam cigarette, or to air (sham), Study A, (mean score ± standard error and incidence).
Localization Tissue type Observation Sham 2R4F Low 2R4F Medium 2R4F High Garam Low Garam Medium Garam High
Nose level 1 Respiratory epithelium Reserve cell hyperplasia 0.0 ± 0.0
0/10
2.0 ± 0.4
9/10⁄⁄⁄
2.9 ± 0.41
0/10⁄⁄⁄
2.8 ± 0.4
9/10⁄⁄⁄
2.3 ± 0.5
8/10⁄⁄⁄
1.6 ± 0.5
8/10⁄⁄⁄
3.1 ± 0.4
10/10⁄⁄⁄
Goblet cell hyperplasia 0.1 ± 0.1
1/10
0.6 ± 0.2
5/10
0.6 ± 0.2
6/10⁄
1.4 ± 0.4
8/10⁄⁄
0.6 ± 0.2
5/10
0.6 ± 0.3
3/10
1.2 ± 0.3
7/10⁄⁄
Loss of goblet cells 0.3 ± 0.2
3/10
1.1 ± 0.2
9/10⁄⁄
2.9 ± 0.3
10/10⁄⁄⁄
1.7 ± 0.3
10/10⁄⁄⁄
1.2 ± 0.2
9/10⁄⁄
1.6 ± 0.4
9/10⁄⁄
2.4 ± 0.4
10/10⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.3 ± 0.2
3/10
0.5 ± 0.2
4/10
0.3 ± 0.2
3/10
0.8 ± 0.4
4/10
0.2 ± 0.1
2/10
0.7 ± 0.3
5/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
1.8 ± 0.6
6/10⁄⁄
2.5 ± 0.5
9/10⁄⁄⁄
1.8 ± 0.5
7/10⁄⁄
2.1 ± 0.6
6/10⁄⁄
1.3 ± 0.5
5/10⁄
2.8 ± 0.4
9/10⁄⁄⁄
Lamina propria Inﬂammatory cell inﬁltration 0.0 ± 0.0
0/10
1.1 ± 0.3
7/10⁄⁄
1.2 ± 0.3
7/10⁄⁄
1.2 ± 0.3
7/10⁄⁄
1.5 ± 0.4
7/10⁄⁄
1.1 ± 0.5
4/10⁄
1.9 ± 0.3
9/10⁄⁄⁄
Lumen Exudate 0.0 ± 0.0
0/10
0.2 ± 0.2
1/10
0.3 ± 0.2
2/10
0.3 ± 0.3
1/10
0.6 ± 0.4
2/10
0.9 ± 0.4
4/10
1.0 ± 0.4
5/10
Nose Level 2 Respiratory epithelium Reserve cell hyperplasia 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.11/10 0.1 ± 0.1
1/10
0.0 ± 0.0 0/10 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory epithelium Atrophy 0.3 ± 0.2
3/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.7 ± 0.3
4/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.3 ± 0.2
3/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.2 ± 0.1
2/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory region Loss of nerve bundles 0.3 ± 0.2
3/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.6 ± 0.3
3/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.3 ± 0.2
3/10
Nose Level 3 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Nose Level 4 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Larynx Ventral depression Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.6 ± 0.3
4/10
0.6 ± 0.3
3/9
1.0 ± 0.4
5/10
0.7 ± 0.3
4/10
0.6 ± 0.3
3/10
1.0 ± 0.4
5/10
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
Vocal cords, lower medial region Hyperplasia without corniﬁcation 0.3 ± 0.2
3/10
1.7 ± 0.2
10/10⁄⁄⁄
2.0 ± 0.0
9/9⁄⁄⁄
2.4 ± 0.3
10/10⁄⁄⁄
2.0 ± 0.1
10/10⁄⁄⁄
1.6 ± 0.2
10/10⁄⁄⁄
1.9 ± 0.2
10/10⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/10
1.1 ± 0.6
3/10
0.9 ± 0.4
4/10⁄
3.4 ± 0.6
9/10⁄⁄⁄
1.5 ± 0.5
6/10⁄⁄
0.6 ± 0.3
3/10
1.7 ± 0.7
5/10⁄
Vocal cords, upper medial region Hyperplasia 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.3 ± 0.2
2/10
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.5 ± 0.3
3/10
2.3 ± 0.5
10/10⁄⁄
2.7 ± 0.3
9/9⁄⁄⁄
2.7 ± 0.5
10/10⁄⁄
1.2 ± 0.4
8/10⁄
0.8 ± 0.3
5/8
1.9 ± 0.5
9/9⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
1.0 ± 0.7
2/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/8
0.0 ± 0.0
0/9
Pseudo-stratiﬁed epithelium Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
3.8 ± 0.5
10/10⁄⁄⁄
4.7 ± 0.2
9/9⁄⁄⁄
4.8 ± 0.1
10/10⁄⁄⁄
3.0 ± 0.6
8/10⁄⁄⁄
4.2 ± 0.4
10/10⁄⁄⁄
4.7 ± 0.2
10/10⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
2.1 ± 0.6
7/10⁄⁄
2.4 ± 0.7
7/9⁄⁄⁄
3.5 ± 0.6
10/10⁄⁄⁄
1.7 ± 0.5
8/10⁄⁄⁄
2.0 ± 0.5
8/10⁄⁄⁄
4.0 ± 0.5
10/10⁄⁄⁄
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Vocal folds Squamous epithelium Hyperplasia without corniﬁcation 0.6 ± 0.2
5/10
1.3 ± 0.2
10/10
1.2 ± 0.1
9/9
1.6 ± 0.3
9/10
1.3 ± 0.2
9/10
0.9 ± 0.3
6/10
1.4 ± 0.2
10/10
Hyperplasia with corniﬁcation 0.1 ± 0.1
1/10
1.1 ± 0.4
5/10⁄
1.4 ± 0.5
5/9⁄
2.5 ± 0.5
8/10⁄⁄
0.8 ± 0.3
5/10⁄
0.9 ± 0.3
5/10⁄
1.0 ± 0.3
6/10⁄
Tracheal bifurcation Respiratory epithelium Goblet cell hyperplasia 0.1 ± 0.1
1/10
0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.2 ± 0.2
1/10
0.1 ± 0.1
1/10
Squamous metaplasia without corniﬁcation 0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Left lung Respiratory epithelium Goblet cell hyperplasia 0.6 ± 0.3
3/10
1.0 ± 0.6
4/8
0.7 ± 0.2
6/9
2.5 ± 0.6
8/10
1.0 ± 0.4
6/10
0.3 ± 0.2
2/8
1.4 ± 0.5
7/10
Lamina propria Inﬂammatory cell inﬁltration 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
(1/10)
Alveoli Alveolar macrophages without pigmentation 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
0.5 ± 0.2
4/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
0.2 ± 0.1
2/10
Alveolar macrophages with pigmentation 0.0 ± 0.0
0/10
0.2 ± 0.1
2/10
0.7 ± 0.2
7/10⁄⁄
1.1 ± 0.2
9/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.4 ± 0.2
4/10⁄
Difference from sham; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Table B
Histopathological ﬁndings in the respiratory tract of female rats after the 90-day inhalation period to MS of the reference cigarette 2R4F, Garam cigarette, or to air (sham), Study A, (mean score ± standard error and incidence).
Localization Tissue type Observation Sham 2R4F Low 2R4F Medium 2R4F High Garam Low Garam Medium Garam High
Nose Level 1 Respiratory epithelium Reserve cell hyperplasia 0.0 ± 0.0
0/10
2.1 ± 0.4
9/10⁄⁄⁄
2.4 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.4
10/10⁄⁄⁄
1.5 ± 0.4
8/10⁄⁄⁄
2.7 ± 0.4
10/10⁄⁄⁄
2.7 ± 0.4
9/10⁄⁄⁄
Goblet cell hyperplasia 0.0 ± 0.0
0/10
0.6 ± 0.3
4/10⁄
1.0 ± 0.2
8/10⁄⁄⁄
0.6 ± 0.2
5/10⁄
1.3 ± 0.4
6/10⁄⁄
1.4 ± 0.5
7/10⁄⁄
1.4 ± 0.3
8/10⁄⁄⁄
Loss of goblet cells 0.3 ± 0.2
3/10
2.1 ± 0.3
10/10⁄⁄⁄
2.9 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.4
10/10⁄⁄⁄
1.4 ± 0.2
10/10⁄⁄⁄
2.4 ± 0.3
10/10⁄⁄⁄
2.6 ± 0.3
10/10⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.7 ± 0.3
4/10⁄
0.9 ± 0.2
7/10⁄⁄
0.8 ± 0.2
7/10⁄⁄
0.9 ± 0.4
5/10⁄
1.0 ± 0.4
7/10⁄⁄
1.1 ± 0.3
8/10⁄⁄⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
2.5 ± 0.5
9/10⁄⁄⁄
3.3 ± 0.4
10/10⁄⁄⁄
3.4 ± 0.4
9/10⁄⁄⁄
2.6 ± 0.5
9/10⁄⁄⁄
3.0 ± 0.5
9/10⁄⁄⁄
3.4 ± 0.3
10/10⁄⁄⁄
Lamina propria Inﬂammatory cell inﬁltration 0.1 ± 0.1
1/10
1.7 ± 0.5
7/10⁄⁄
1.7 ± 0.3
9/10⁄⁄⁄
1.9 ± 0.3
10/10⁄⁄⁄
0.8 ± 0.2
6/10⁄
2.4 ± 0.4
9/10⁄⁄⁄
2.2 ± 0.4
10/10⁄⁄⁄
Lumen Exudate 0.0 ± 0.0
0/10
1.0 ± 0.5
3/10
0.7 ± 0.4
3/10
1.1 ± 0.4
5/10⁄
0.1 ± 0.1
1/10
2.0 ± 0.5
7/10⁄⁄
1.4 ± 0.5
7/10⁄⁄
Nose Level 2 Respiratory epithelium Reserve cell hyperplasia 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.5 ± 0.2
5/10⁄
0.7 ± 0.3
5/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.6 ± 0.2
6/10
0.2 ± 0.1
2/10
0.8 ± 0.1
8/10
0.9 ± 0.2
8/10
0.1 ± 0.1
1/10⁄
0.3 ± 0.2
3/10
0.2 ± 0.1
2/10
Olfactory epithelium Atrophy 0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
2.0 ± 0.6
6/10⁄
3.0 ± 0.6
9/10⁄⁄⁄
0.0 ± 0.0
0/10
0.2 ± 0.1
2/10
0.2 ± 0.1
2/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.9 ± 0.4
4/10⁄
2.1 ± 0.6
7/10⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
(continued on next page)
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Table B (continued)
Localization Tissue type Observation Sham 2R4F Low 2R4F Medium 2R4F High Garam Low Garam Medium Garam High
Olfactory region Loss of nerve bundles 0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
1.7 ± 0.7
5/10⁄
3.0 ± 0.6
9/10⁄⁄⁄
0.0 ± 0.0
0/10
0.2 ± 0.1
2/10
0.2 ± 0.1
2/10
Nose Level 3 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.4
3/10
1.8 ± 0.6
5/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.4 ± 0.3
2/10
0.8 ± 0.3
4/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.4
3/10
1.8 ± 0.6
5/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Nose Level 4 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.6 ± 0.4
2/10
1.6 ± 0.7
4/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.4 ± 0.4
1/10
1.4 ± 0.6
4/10⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.2 ± 0.1
1/10
0.4 ± 0.4
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Larynx Ventral depression Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.6 ± 0.3
4/10⁄
2.3 ± 0.5
9/10⁄⁄⁄
2.3 ± 0.4
10/10⁄⁄⁄
1.0 ± 0.4
6/10⁄⁄
0.6 ± 0.2
6/10⁄⁄
1.3 ± 0.4
8/10⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.3 ± 0.2
2/10
0.4 ± 0.2
3/10
0.3 ± 0.3
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Vocal cords, lower medial region Hyperplasia without corniﬁcation 0.6 ± 0.2
5/10
2.2 ± 0.2
10/10⁄⁄⁄
2.7 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.3
10/10⁄⁄⁄
2.1 ± 0.2
10/10⁄⁄⁄
2.8 ± 0.2
10/10⁄⁄⁄
2.3 ± 0.2
10/10⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/10
1.6 ± 0.6
5/10⁄
3.7 ± 0.7
8/10⁄⁄⁄
2.5 ± 0.8
6/10⁄⁄
0.3 ± 0.2
2/10⁄⁄
4.2 ± 0.5
9/10⁄⁄⁄
3.6 ± 0.7
8/10⁄⁄⁄
Vocal cords, upper medial region Squamous metaplasia without corniﬁcation 0.4 ± 0.3
2/7
2.0 ± 0.5
9/9
3.1 ± 0.6
10/10
3.0 ± 0.4
9/9
2.4 ± 0.6
8/8
3.4 ± 0.6
10/10
3.4 ± 0.6
9/9
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/7
1.1 ± 0.7
2/9
1.9 ± 0.8
4/10
0.6 ± 0.5
2/10
0.0 ± 0.0
0/8
2.4 ± 0.8
5/10
2.2 ± 0.9
4/9
Pseudo-stratiﬁed epithelium Squamous metaplasia without corniﬁcation 0.1 ± 0.1
1/10
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
4.6 ± 0.2
10/10⁄⁄⁄
4.9 ± 0.1
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
4.2 ± 0.3
10/10⁄⁄⁄
4.7 ± 0.2
10/10⁄⁄⁄
4.8 ± 0.1
10/10⁄⁄⁄
2.9 ± 0.5
9/10⁄⁄⁄
4.2 ± 0.3
10/10⁄⁄⁄
4.9 ± 0.1
10/10⁄⁄⁄
Vocal folds Squamous epithelium Hyperplasia without corniﬁcation 0.1 ± 0.1
1/10
1.7 ± 0.2
10/10⁄⁄⁄
1.6 ± 0.2
9/10⁄⁄⁄
1.5 ± 0.2
9/10⁄⁄⁄
1.5 ± 0.2
9/10⁄⁄⁄
1.7 ± 0.2
10/10⁄⁄⁄
1.8 ± 0.1
10/10⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/10
2.1 ± 0.4
8/10⁄⁄⁄
3.1 ± 0.7
9/10⁄⁄⁄
2.1 ± 0.7
5/10⁄
1.4 ± 0.4
6/10⁄⁄
2.7 ± 0.6
8/10⁄⁄⁄
3.4 ± 0.6
9/10⁄⁄⁄
Tracheal bifurcation Respiratory epithelium Goblet cell hyperplasia 0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.2 ± 0.1
2/10
0.4 ± 0.2
3/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Squamous metaplasia without corniﬁcation 0.3 ± 0.2
3/10
0.1 ± 0.1
1/10
0.3 ± 0.2
3/10
0.1 ± 0.1
1/10
0.2 ± 0.1
2/10
0.1 ± 0.1
1/10
0.3 ± 0.2
2/10
Left lung Respiratory epithelium Goblet cell hyperplasia 0.9 ± 0.4
5/10
2.0 ± 0.6
8/10
2.1 ± 0.6
8/9⁄
3.4 ± 0.5
10/10⁄⁄
0.7 ± 0.3
4/10⁄⁄
0.8 ± 0.4
4/10
3.2 ± 0.5
9/9⁄⁄
Lamina propria Inﬂammatory cell inﬁltration 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
Alveoli Alveolar macrophages without pigmentation 0.2 ± 0.1
2/10
0.6 ± 0.2
6/10
0.8 ± 0.1
7/9⁄⁄
0.9 ± 0.1
9/10⁄⁄
0.2 ± 0.1
2/10
0.5 ± 0.2
5/10
0.6 ± 0.2
6/10
Alveolar macrophages with pigmentation 0.0 ± 0.0
0/10
0.6 ± 0.2
6/10⁄⁄
1.4 ± 0.2
9/9⁄⁄⁄
1.5 ± 0.2
10/10⁄⁄⁄
0.3 ± 0.2
3/10
0.7 ± 0.2
6/10⁄⁄
0.5 ± 0.2
5/10⁄
Difference from Sham; signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
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Table C
Histopathological ﬁndings in the respiratory tract of male rats after the 90-day inhalation period to MS of the reference cigarette 2R4F,Kretek-R cigarette, or to air (sham), Study B, (mean score ± standard error and incidence).
Localization Tissue type Observation Sham 2R4F low 2R4F Medium 2R4F High Kretek-R Low Kretek-R Medium Kretek-R High
Nose Level 1 Respiratory epithelium Reserve cell hyperplasia 0.1 ± 0.1
1/10
3.0 ± 0.1
10/10⁄⁄⁄
4.0 ± 0.0
9/9⁄⁄⁄
3.9 ± 0.1
9/9⁄⁄⁄
2.7 ± 0.3
10/10⁄⁄⁄
3.4 ± 0.2
10/10⁄⁄⁄
3.7 ± 0.2
9/9⁄⁄⁄
Goblet cell hyperplasia 0.0 ± 0.0
0/10
0.3 ± 0.3
2/10
1.0 ± 0.3
6/9⁄⁄
0.9 ± 0.3
6/9⁄⁄
0.9 ± 0.4
6/10⁄⁄
1.5 ± 0.3
8/10⁄⁄⁄
0.9 ± 0.3
6/9⁄⁄
Loss of goblet cells 0.2 ± 0.1
2/10
2.7 ± 0.3
10/10⁄⁄⁄
3.4 ± 0.2
9/9⁄⁄⁄
4.0 ± 0.2
9/9⁄⁄⁄
2.5 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.3
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.3
4/9⁄
1.9 ± 0.4
7/9⁄⁄⁄
0.0 ± 0.0
0/10
0.5 ± 0.3
2/10
0.0 ± 0.0
0/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
1.7 ± 0.2
10/10⁄⁄⁄
3.2 ± 0.3
9/9⁄⁄⁄
3.7 ± 0.2
9/9⁄⁄⁄
1.5 ± 0.4
7/10⁄⁄
2.3 ± 0.4
10/10⁄⁄⁄
2.4 ± 0.3
9/9⁄⁄⁄
Nose Level 2 Respiratory epithelium Reserve cell hyperplasia 0.2 ± 0.1
2/10
1.3 ± 0.2
10/10⁄⁄⁄
2.8 ± 0.2
10/10⁄⁄⁄
3.7 ± 0.2
9/9⁄⁄⁄
1.0 ± 0.2
8/10⁄⁄
1.4 ± 0.2
10/10⁄⁄⁄
1.6 ± 0.2
9/9⁄⁄⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.6 ± 0.2
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory epithelium Atrophy 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
1.7 ± 0.5
8/10⁄⁄⁄
2.8 ± 0.4
9/9⁄⁄⁄
0.2 ± 0.1
2/10
0.0 ± 0.0
0/10
0.8 ± 0.3
5/9⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.9 ± 0.4
4/10⁄
1.4 ± 0.5
5/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.8 ± 0.3
4/10⁄
2.0 ± 0.5
7/9⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.2 ± 0.1
2/9
Nose Level 3 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
1.5 ± 0.6
5/10⁄
1.8 ± 0.7
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.3
4/10⁄
1.4 ± 0.6
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.3
4/10⁄
1.3 ± 0.6
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Nose Level 4 Olfactory epithelium Atrophy 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.8 ± 0.4
3/10
1.2 ± 0.5
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.4 ± 0.3
2/10
1.2 ± 0.5
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.4 ± 0.2
3/10
1.0 ± 0.5
4/9⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Larynx Ventral depression Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
1.1 ± 0.2
8/10⁄⁄⁄
2.3 ± 0.4
9/10⁄⁄⁄
3.4 ± 0.5
9/9⁄⁄⁄
1.6 ± 0.5
8/9⁄⁄⁄
1.9 ± 0.6
7/10⁄⁄
2.1 ± 0.5
7/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
1.1 ± 0.7
3/9
0.2 ± 0.2
1/9
0.5 ± 0.5
1/10
0.6 ± 0.6
1/9
Vocal cords, LMR Hyperplasia without corniﬁcation 0.0 ± 0.0
0/10
2.6 ± 0.3
10/10⁄⁄⁄
3.6 ± 0.2
10/10⁄⁄⁄
4.0 ± 0.0
9/9⁄⁄⁄
3.2 ± 0.3
9/9⁄⁄⁄
3.6 ± 0.2
8/8⁄⁄⁄
3.8 ± 0.1
9/9⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/10
0.7 ± 0.5
2/10
2.3 ± 0.5
7/10⁄⁄
3.1 ± 0.5
8/8⁄⁄⁄
2.3 ± 0.6
7/9⁄⁄⁄
1.9 ± 0.7
5/9⁄⁄
3.3 ± 0.5
8/9⁄⁄⁄
Vocal cords, UMR Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
1.4 ± 0.5
7/10⁄⁄
2.7 ± 0.5
10/10⁄⁄⁄
3.9 ± 0.1
7/7⁄⁄⁄
1.4 ± 0.5
5/9⁄⁄
2.6 ± 0.4
9/9⁄⁄⁄
3.4 ± 0.3
9/9⁄⁄⁄
Pseudo-stratiﬁed epithelium Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
4.7 ± 0.2
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
9/9⁄⁄⁄
5.0 ± 0.0
9/9⁄⁄⁄
4.9 ± 0.1
10/10⁄⁄⁄
4.9 ± 0.1
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
3.8 ± 0.4
10/10⁄⁄⁄
4.6 ± 0.2
10/10⁄⁄⁄
4.9 ± 0.1
9/9⁄⁄⁄
4.7 ± 0.2
9/9⁄⁄⁄
4.5 ± 0.3
10/10⁄⁄⁄
4.9 ± 0.1
9/9⁄⁄⁄
Vocal folds Pseudo-stratiﬁed epithelium Reserve cell hyperplasia 0.0 ± 0.0
0/10
0.8 ± 0.2
6/10⁄⁄
1.2 ± 0.2
9/10⁄⁄⁄
1.9 ± 0.3
7/7⁄⁄⁄
0.8 ± 0.3
4/8⁄
1.4 ± 0.3
7/8⁄⁄⁄
1.4 ± 0.4
6/7⁄⁄⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/7
0.0 ± 0.0
0/8
0.0 ± 0.0
0/8
0.0 ± 0.0
0/7
Squamous epithelium Hyperplasia without corniﬁcation 0.0 ± 0.0
0/10
1.3 ± 0.4
6/10⁄⁄
2.7 ± 0.4
9/10⁄⁄⁄
3.3 ± 0.3
7/7⁄⁄⁄
2.1 ± 0.2
8/8⁄⁄⁄
2.6 ± 0.3
8/8⁄⁄⁄
3.4 ± 0.2
7/4⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0 0.9 ± 0.4 2.8 ± 0.4 4.0 ± 0.4 2.1 ± 0.4 2.8 ± 0.5 3.9 ± 0.3
(continued on next page)
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Table C (continued)
Localization Tissue type Observation Sham 2R4F low 2R4F Medium 2R4F High Kretek-R Low Kretek-R Medium Kretek-R High
0/10 4/10⁄ 9/10⁄⁄⁄ 7/7⁄⁄⁄ 7/8⁄⁄⁄ 7/8⁄⁄⁄ 7/7⁄⁄⁄
Tracheal bifurcation Respiratory epithelium Goblet cell hyperplasia 0.4 ± 0.2
4/10
0.2 ± 0.1
2/9
1.0 ± 0.2
8/9⁄
1.3 ± 0.3
7/8⁄
0.2 ± 0.1
2/9
0.6 ± 0.2
5/9
0.8 ± 0.3
4/8
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/9
0.0 ± 0.0
0/8
0.0 ± 0.0
0/8
0.0 ± 0.0
0/6
0.0 ± 0.0
0/8
0.1 ± 0.1
1/9
0.1 ± 0.1
1/7
Left lung Respiratory epithelium Goblet cell hyperplasia 0.7 ± 0.6
2/9
0.8 ± 0.2
5/6
2.3 ± 0.4
9/10⁄
3.9 ± 0.4
7/7⁄⁄
0.8 ± 0.2
6/10
2.0 ± 0.4
10/10⁄⁄
2.7 ± 0.6
7/7⁄⁄
Alveoli Alveolar macrophages without pigmentation 0.2 ± 0.1
2/10
1.4 ± 0.2
10/10⁄⁄⁄
2.0 ± 0.0
10/10⁄⁄⁄
2.8 ± 0.1
9/9⁄⁄⁄
0.8 ± 0.1
8/10⁄⁄
1.4 ± 0.2
10/10⁄⁄⁄
1.6 ± 0.2
9/9⁄⁄⁄
Alveolar macrophages with pigmentation 0.0 ± 0.0
0/10
1.9 ± 0.2
10/10⁄⁄⁄
2.7 ± 0.2
10/10⁄⁄⁄
3.4 ± 0.2
9/9⁄⁄⁄
1.0 ± 0.2
8/10⁄⁄⁄
1.9 ± 0.1
10/10⁄⁄⁄
2.0 ± 0.2
9/9⁄⁄⁄
Difference from Sham; Signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
Table D
Histopathological ﬁndings in the respiratory tract of female rats after the 90-day inhalation period to MS of the reference cigarette 2R4F, Kretek-R cigarette, or to air (sham), Study B, (mean score ± standard error and incidence).
Localization Tissue type Observation Sham 2R4F Low 2R4F Medium 2R4F High Kretek-R Low Kretek-R Medium Kretek-R High
Nose Level 1 Respiratory epithelium Reserve cell hyperplasia 0.1 ± 0.1
1/10
3.3 ± 0.2
10/10⁄⁄⁄
4.0 ± 0.0
10/10⁄⁄⁄
4.0 ± 0.0
10/10⁄⁄⁄
3.1 ± 0.2
10/10⁄⁄⁄
3.7 ± 0.2
10/10⁄⁄⁄
4.0 ± 0.0
9/9⁄⁄⁄
Goblet cell hyperplasia 0.0 ± 0.0
0/10
0.3 ± 0.2
3/10
0.8 ± 0.2
7/10⁄⁄
0.6 ± 0.2
3/10⁄
0.4 ± 0.2
4/10⁄
0.4 ± 0.2
4/10⁄
1.1 ± 0.2
8/9⁄⁄⁄
Loss of goblet cells 0.3 ± 0.2
3/10
3.6 ± 0.2
10/10⁄⁄⁄
4.4 ± 0.2
10/10⁄⁄⁄
4.7 ± 0.2
10/10⁄⁄⁄
3.2 ± 0.2
10/10⁄⁄⁄
4.1 ± 0.2
10/10⁄⁄⁄
4.1 ± 0.1
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
1.8 ± 0.4
7/10⁄⁄
2.4 ± 0.3
9/10⁄⁄⁄
0.4 ± 0.3
2/10
0.9 ± 0.3
5/10⁄
1.0 ± 0.4
4/9⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
2.5 ± 0.3
10/10⁄⁄⁄
3.7 ± 0.2
10/10⁄⁄⁄
3.9 ± 0.1
10/10⁄⁄⁄
2.4 ± 0.3
10/10⁄⁄⁄
3.2 ± 0.3
10/10⁄⁄⁄
3.6 ± 0.2
9/9⁄⁄⁄
Nose Level 2 Respiratory epithelium Reserve cell hyperplasia 0.1 ± 0.1
1/10
1.4 ± 0.2
9/10⁄⁄⁄
2.5 ± 0.2
10/10⁄⁄⁄
3.6 ± 0.2
10/10⁄⁄⁄
0.5 ± 0.2
5/10
0.9 ± 0.1
9/10⁄⁄⁄
1.6 ± 0.2
9/9⁄⁄⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.4 ± 0.2
3/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.5 ± 0.2
4/10⁄
1.9 ± 0.5
7/10⁄⁄
3.5 ± 0.3
10/10⁄⁄⁄
0.1 ± 0.1
1/10
0.0 ± 0.0
0/10
1.4 ± 0.3
7/9⁄⁄⁄
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.7 ± 0.4
3/10
1.9 ± 0.4
8/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/9
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.9 ± 0.3
5/10⁄
3.1 ± 0.2
10/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
1.1 ± 0.4
5/9⁄⁄
Nose Level 3 Olfactory epithelium Atrophy 0.1 ± 0.1
1/10
0.3 ± 0.3
1/10
1.0 ± 0.5
3/10
3.5 ± 0.3
10/10⁄⁄⁄
0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
0.8 ± 0.4
3/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.9 ± 0.5
3/10
2.4 ± 0.5
8/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.1 ± 0.1
1/9
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Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.2 ± 0.2
1/10
0.7 ± 0.4
3/10
2.9 ± 0.5
9/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.6 ± 0.3
3/9
Nose Level 4 Olfactory epithelium Atrophy 0.0 ± 0.0
0/10
0.2 ± 0.2
1/10
0.7 ± 0.4
3/10
2.3 ± 0.4
8/10⁄⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.3 ± 0.3
1/10
1.5 ± 0.5
6/10⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Olfactory region Loss of nerve bundles 0.0 ± 0.0
0/10
0.1 ± 0.1
1/10
0.4 ± 0.2
3/10
1.8 ± 0.5
7/10⁄⁄
0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.0 ± 0.0
0/9
Larynx Ventral depression Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/10
1.6 ± 0.5
8/10⁄⁄⁄
2.7 ± 0.5
8/9⁄⁄⁄
3.9 ± 0.4
10/10⁄⁄⁄
1.1 ± 0.2
8/9⁄⁄⁄
2.6 ± 0.4
9/9⁄⁄⁄
3.0 ± 0.4
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
0.0 ± 0.0
0/10
0.6 ± 0.4
2/9
0.9 ± 0.5
3/10
0.0 ± 0.0
0/9
0.0 ± 0.0
0/9
0.3 ± 0.3
1/9
Vocal cords, lower medial region Hyperplasia without corniﬁcation 0.0 ± 0.0
0/9
3.7 ± 0.2
10/10⁄⁄⁄
3.8 ± 0.2
10/10⁄⁄⁄
3.9 ± 0.1
10/10⁄⁄⁄
3.9 ± 0.1
10/10⁄⁄⁄
4.0 ± 0.0
9/9⁄⁄⁄
4.3 ± 0.2
9/9⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/9
3.0 ± 0.5
8/10⁄⁄⁄
3.7 ± 0.5
9/10⁄⁄⁄
4.1 ± 0.2
10/10⁄⁄⁄
3.8 ± 0.2
10/10⁄⁄⁄
4.3 ± 0.2
9/9⁄⁄⁄
4.0 ± 0.2
9/9⁄⁄⁄
Vocal cords, upper medial region Squamous metaplasia without corniﬁcation 0.0 ± 0.0
0/9
3.4 ± 0.5
9/10⁄⁄⁄
3.7 ± 0.6
9/10⁄⁄⁄
3.7 ± 0.4
9/9⁄⁄⁄
2.9 ± 0.5
9/9⁄⁄⁄
4.0 ± 0.7
7/7⁄⁄⁄
3.7 ± 0.4
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/9
0.0 ± 0.0
0/10
1.2 ± 0.6
3/10
0.8 ± 0.6
2/9
0.3 ± 0.3
1/9
1.9 ± 0.9
3/7
1.1 ± 0.7
2/9
Pseudo-stratiﬁed epithelium Squamous metaplasia without corniﬁcation 0.2 ± 0.2
1/10
4.9 ± 0.1
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
5.0 ± 0.0
9/9⁄⁄⁄
Squamous metaplasia with corniﬁcation 0.0 ± 0.0
0/10
4.7 ± 0.2
10/10⁄⁄⁄
4.8 ± 0.2
10/10⁄⁄⁄
5.0 ± 0.0
10/10⁄⁄⁄
4.8 ± 0.2
10/10⁄⁄⁄
4.9 ± 0.2
10/10⁄⁄⁄
5.0 ± 0.0
9/9⁄⁄⁄
Vocal folds Pseudo-stratiﬁed epithelium Reserve cell hyperplasia 0.1 ± 0.1
1/10
0.3 ± 0.2
3/9
1.4 ± 0.21
0/10⁄⁄⁄
1.9 ± 0.2
10/10⁄⁄⁄
0.7 ± 0.2
5/9⁄
1.2 ± 0.2
9/10⁄⁄⁄
1.4 ± 0.3
7/8⁄⁄
Squamous epithelium Hyperplasia without corniﬁcation 0.2 ± 0.1
2/10
2.2 ± 0.4
8/9⁄⁄
2.9 ± 0.3
10/10⁄⁄⁄
3.7 ± 0.2
10/10⁄⁄⁄
2.7 ± 0.2
9/9⁄⁄⁄
3.1 ± 0.3
10/10⁄⁄⁄
3.3 ± 0.3
8/8⁄⁄⁄
Hyperplasia with corniﬁcation 0.0 ± 0.0
0/10
1.9 ± 0.5
6/9⁄⁄
3.1 ± 0.4
9/10⁄⁄⁄
4.1 ± 0.2
10/10⁄⁄⁄
2.7 ± 0.4
9/9⁄⁄⁄
3.2 ± 0.4
9/10⁄⁄⁄
3.3 ± 0.3
8/8⁄⁄⁄
Tracheal bifurcation Respiratory epithelium Goblet cell hyperplasia 0.8 ± 0.3
(5/9)
0.1 ± 0.1
1/10
0.7 ± 0.3
5/10
0.8 ± 0.1
8/10
0.3 ± 0.2
3/10
0.4 ± 0.2
3/10
0.8 ± 0.1
7/9
Squamous metaplasia without corniﬁcation 0.0 ± 0.0
(0/8)
0.0 ± 0.0
0/10
0.1 ± 0.1
1/9
0.4 ± 0.2
3/9
0.1 ± 0.1
1/9
0.1 ± 0.1
1/10
0.0 ± 0.0
0/8
Left lung Respiratory epithelium Goblet cell hyperplasia 0.5 ± 0.3
3/8
0.9 ± 0.3
6/9
2.2 ± 0.4
10/10⁄⁄
4.0 ± 0.3
8/8⁄⁄⁄
0.7 ± 0.2
6/9
1.5 ± 0.4
8/10
2.4 ± 0.4
7/7⁄⁄
Alveoli Alveolar macrophages without pigmentation 0.3 ± 0.2
3/10
2.2 ± 0.1
10/10⁄⁄⁄
2.7 ± 0.2
10/10⁄⁄⁄
2.4 ± 0.2
10/10⁄⁄⁄
1.2 ± 0.1
10/10⁄⁄
1.7 ± 0.2
10/10⁄⁄⁄
2.1 ± 0.2
9/9⁄⁄⁄
Alveolar macrophages with pigmentation 0.2 ± 0.1
2/10
2.5 ± 0.3
10/10⁄⁄⁄
3.0 ± 0.11
0/10⁄⁄⁄
3.0 ± 0.1
10/10⁄⁄⁄
1.2 ± 0.1
10/10⁄⁄⁄
1.9 ± 0.2
10/10⁄⁄⁄
2.2 ± 0.1
9/9⁄⁄⁄
Difference from sham; Signiﬁcance: ⁄p < 0.05; ⁄⁄p < 0.01; and ⁄⁄⁄p < 0.001 (p-value from 2-way ANOVA followed by Dunnett posthoc test).
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of the smoke of kretek cigarettes compared to conventional Amer-
ican-blended cigarettes.
5. Conclusions
Classical toxicology endpoints from two 90-day inhalation stud-
ies on two kretek cigarettes and an American-blended reference
cigarette provided insight into their comparative toxicity, with
the aim of providing a basis for hazard characterization. The obser-
vations were consistent with what has been observed in previously
published MS inhalation studies in rodents. Nevertheless, kretek
cigarette smoke exposure was associated with signiﬁcantly lower
pulmonary inﬂammation and histopathological changes in the
respiratory tract. These results are consistent with the observa-
tions made on smoke chemistry and in vitro toxicology. They do
not support any increased toxicity of the smoke of kretek cigarettes
compared to conventional American-blended cigarettes.
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